IMMUNOTHERAPY
Latest News
April 2nd 2019
By Wayne Kuznar
The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.
Latest Videos
More News
Consuming a diet rich in fiber could boost immunotherapy response in select patients with melanoma, according to early research findings.
Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.
To date, there is no national Medicare policy in place to provide coverage for CAR T-cell therapies, which have been proven to be a successful treatment for certain patients with relapsed/refractory cancers. Now, the Centers for Medicare & Medicaid Services has proposed to cover CAR T-cell therapies approved by the FDA under “Coverage with Evidence Development."
Arjun V. Balar, MD, discusses a few approaches for incorporating immunotherapy treatments into the frontline for patients with bladder cancer.
Ezra Cohen, MD, discusses the advancing field of immunotherapy in the treatment landscape for patients with head and neck cancers. Prior to the use of PD-1/PD-L1 blockades, which have been the most tested immunotherapy in this setting, there were little treatment options.
